Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06300411 · ClinicalTrials.gov registry record · Phase 1

SRG-514 Administered Intraoperatively to Patients Undergoing Breast-conserving Cancer Surgery

A Phase 1 study of Breast Cancer, sponsored by SURGE Therapeutics.

Active
Registry status
Phase 1
Development phase
24
Enrollment target
8
Study locations

NCT06300411 is a Phase 1 study of Breast Cancer that is active but no longer recruiting, run by SURGE Therapeutics. The registered enrollment target is 24 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 8 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06300411, a Phase 1 study of Breast Cancer, is active but no longer recruiting, sponsored by SURGE Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
24 participants
Enrollment target
8
Study locations

Study Summary

This is a multicenter, first-in-human (FIH), open label, Phase 1 dose escalation and recommended Phase 2 dose (RP2D) extension trial with a primary objective to define the RP2D of SRG-514 when administered intraoperatively to patients undergoing breast-conserving cancer surgery. SRG-514 will be investigated utilizing a 3+3 convention dose escalation cohorts.

Conditions Studied

Breast Cancer

Interventions

  • DRUG SRG-514

Study Locations (8)

Texas

  • MD Anderson Cancer Center - Houston
  • Audie Murphy VA - San Antonio

Georgia

  • Memorial Health - Savannah

Indiana

  • Indiana University - Indianapolis

Minnesota

  • Mayo - Rochester

Missouri

  • Washington University School of Medicine - St Louis

New York

  • NYU Langone Health - New York

North Carolina

  • Duke Cancer Center - Durham

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2024-07-29
Est. Completion 2026-04-10
Phase Phase 1

Sponsor

SURGE Therapeutics

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06300411

The ClinicalTrials.gov registry entry for NCT06300411 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is SURGE Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which SRG-514 is the first listed.

NCT06300411 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Texas, Georgia, Indiana.

Frequently Asked Questions

What is clinical trial NCT06300411 about?

NCT06300411 is a clinical study titled "SRG-514 Administered Intraoperatively to Patients Undergoing Breast-conserving Cancer Surgery". This is a multicenter, first-in-human (FIH), open label, Phase 1 dose escalation and recommended Phase 2 dose (RP2D) extension trial with a primary objective to define the RP2D of SRG-514 when administered intraoperatively to patients undergoing breast-conserving cancer surgery. SRG-514 will be inve...

What is the current status of trial NCT06300411?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2024-07-29. Estimated completion is 2026-04-10.

What conditions does trial NCT06300411 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT06300411?

The interventions under investigation include: SRG-514 (DRUG).

Who is sponsoring clinical trial NCT06300411?

This trial is sponsored by SURGE Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06300411 being conducted?

This trial has 8 study locations across Georgia, Indiana, Minnesota, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.